Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-03-03
1996-10-15
Criares, Theodore J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
5142282, 5142312, 514245, 514269, 514261, 514359, 514369, 514396, 514406, 514408, 514418, 514430, 514432, 514461, 514468, 514756, A61K 31505, A61K 3154, A61K 31535, A61K 3153
Patent
active
055654606
DESCRIPTION:
BRIEF SUMMARY
This application is filed under 35 USC 371 of PCT/JP94101196 filed Jul. 20, 1994 which claims parity of Japan application 184,295 filed Jul. 27, 1983.
TECHNICAL FIELD
The present invention relates to a therapeutic agent for Parkinson's disease.
BACKGROUND ART
In connection with Compounds (I) (described afterward) in the present invention, it is known that compounds represented by the following formula ##STR3## in which R.sup.1a represents hydrogen, substituted or unsubstituted lower alkyl, or lower alkanoyl, R.sup.2a represents hydrogen, lower alkenyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted phenyl, substituted or unsubstituted aralkyl, or a substituted or unsubstituted heterocyclic group, R.sup.3a represents a substituted or unsubstituted 5-membered heterocyclic group, X.sup.a represents O, S, S(O), S(O).sub.2, or NR.sup.4a (in, which R.sup.4a represents hydrogen, or substituted or unsubstituted lower alkyl, or R.sup.2a and NR.sup.4a are combined to form a substituted or unsubstituted 4 to 6-membered saturated heterocyclic group), and A.sup.a represents N or CR.sup.5a (in which R.sup.5a represents hydrogen, or substituted or unsubstituted lower alkyl), and compounds represented by the following formula ##STR4## in which R.sup.1b represents hydrogen, substituted or unsubstituted lower alkyl, or lower alkanoyl, R.sup.2b represents substituted or unsubstituted lower alkyl, lower alkenyl, lower alkynyl, substituted or unsubstituted phenyl, or a substituted or unsubstituted 5- or 6-membered heterocyclic group, and A.sup.b represents N or CR.sup.5b (in which R.sup.5b represents hydrogen, or substituted or unsubstituted lower alkyl), have an selective adenosine A.sub.2 antagonistic activity (Japanese Published Unexamined Patent Application No. 97855.93 and EP 515107A).
Further, in connection with Compounds (II) (described afterward), it is known that compounds represented by the following formula ##STR5## in which R.sup.6a represents substituted or unsubstituted phenyl, or a substituted or unsubstituted heterocyclic group, Y.sup.a represents O, S, or NR.sup.7a (in which R.sup.7a represents hydrogen, substituted or unsubstituted lower alkyl, lower alkenyl, lower alkynyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted aryl), R.sup.8a represents hydrogen, substituted or unsubstituted lower alkyl, lower alkenyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl, and B.sup.a and the adjacent two carbon atoms are combined to form a substituted or unsubstituted, saturated or unsaturated, monocyclic or bicyclic, carbocyclic or heterocyclic group, have an adenosine A.sub.2 antagonistic activity and exhibits an antispasmic activity and a bronchodilating activity [Japanese Published Unexamined Patent Application Nos. 165386/86 and 135475/87, J. Med. Chem., 31, 1014 (1988)].
DISCLOSURE OF THE INVENTION
The present invention relates to a therapeutic agent for Parkinson's disease containing as an active ingredient a polycyclic compound, or a pharmaceutically acceptable salt thereof, the compound being represented by the following Formula (I): ##STR6## in which, R.sup.1 represents hydrogen substituted or unsubstituted lower alkyl, or substituted or unsubstituted lower alkanoyl; R.sup.2 represents hydrogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl, or a substituted or unsubstituted heterocyclic group; R.sup.3 represents a substituted or unsubstituted heterocyclic group; X represents a single bond, O, S, S(O), S(O).sub.2, or NR.sup.4 (in which R.sup.4 represents hydrogen, or substituted or unsubstituted lower alkyl; or R.sup.2 and NR.sup.4 are combined to form a substituted or unsubstituted 4 to 6-membered saturated heterocyclic group); and A represents N or CR.sup.5 (in which R.sup.5 represents hydrogen, or substituted or unsubstituted lower alkyl), or represented by the following For
REFERENCES:
patent: 4831013 (1989-05-01), Francis
patent: 5356894 (1994-10-01), Rodney et al.
Francis, J. E. "Structure-Activity Profile of a Series of Novel Triazoloquinazoline Adenosine Antagonists", J. Med. Chem. 31: 1014-1020, 1988.
Ichikawa Shunji
Kanda Tomoyuki
Kitamura Shigeto
Koike Nobuaki
Nakamura Joji
Criares Theodore J.
Kyowa Hakko Koygo Co., Ltd.
LandOfFree
Therapeutic purine agents for parkinson's disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic purine agents for parkinson's disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic purine agents for parkinson's disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1246347